BioStock: Interview with CombiGene's new CMC expert
The Swedish Gene Therapy Company CombiGene aims to complete its preclinical program for the epilepsy project CG01 this year, in order to begin studies in humans in 2022. In this transitional phase, CombiGene has accelerated its recruitment process to occupy several key positions. BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01.
Read the full interview with Martin Linhult at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/